Avacta Group plc (AIM: AVCT) a life sciences company developing innovative, targeted oncology drugs, is pleased to announce today that its pre|CISION® platform has been shortlisted for the AIM Technology of the Year Award. The AIM Awards is the flagship event for AIM and is held annually, in London, to celebrate success and achievement amongst the world’s fastest growing publicly quoted companies. The Awards identify the quoted companies and entrepreneurs who have harnessed AIM to help them fulfil their ambition and growth potential in the last twelve months. The Awards will be distributed at the event on October 1, 2025.
Christina Coughlin, CEO of Avacta commented:
“We are delighted to be on the shortlist for Technology of the Year among companies listed on the AIM market. Our pre|CISION® technology changes the way that potent cancer therapies are delivered to patients, where the drug is silent in the bloodstream yet active in the tumor, allowing cancer cells to be targeted while preserving patient vitality. We look forward to the event next month.”